标题
Immunogenicity of biologic agents in rheumatology
作者
关键词
-
出版物
Nature Reviews Rheumatology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-12-14
DOI
10.1038/s41584-020-00540-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Immunogenicity of TNF-Inhibitors
- (2020) Sadaf Atiqi et al. Frontiers in Immunology
- Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD
- (2020) Evy Ulijn et al. ANNALS OF THE RHEUMATIC DISEASES
- Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies
- (2020) Takashi Kei Kishimoto Frontiers in Immunology
- Pretreatment and Coadministration With Methotrexate Improved Durability of Pegloticase Response
- (2020) John K. Botson et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Immunogenicity assay development and validation for biologic therapy as exemplified by ustekinumab
- (2019) Sorwe Mojtahed Poor et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay
- (2019) Lea C. Berkhout et al. Science Translational Medicine
- Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept
- (2019) Thierry Dervieux et al. ANNALS OF THE RHEUMATIC DISEASES
- Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk
- (2019) Nicoletta Bivi et al. mAbs
- Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis
- (2019) A. Deodhar et al. JOURNAL OF RHEUMATOLOGY
- The Neonatal Fc Receptor (FcRn): A Misnomer?
- (2019) Michal Pyzik et al. Frontiers in Immunology
- Methotrexate Reduces the Clearance of Adalimumab by Increasing the Concentration of Neonatal Fc Receptor in Tissues
- (2019) Yuwei Deng et al. PHARMACEUTICAL RESEARCH
- Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
- (2019) Vibeke Strand et al. BIODRUGS
- The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients
- (2019) Lea C Berkhout et al. RHEUMATOLOGY
- Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition
- (2018) J. Goncalves et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies
- (2018) Karin A van Schie et al. ANNALS OF THE RHEUMATIC DISEASES
- Methotrexate and BAFF interaction prevents immunization against TNF inhibitors
- (2018) Samuel Bitoun et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab
- (2018) B. Gorovits et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
- (2018) Hillel P. Cohen et al. DRUGS
- Editorial: Magnetic Resonance Imaging Signals in the Sacroiliac Joints of Healthy Athletes: Refining Disease Thresholds and Treatment Strategies in Axial Spondyloarthritis
- (2018) Christopher Ritchlin Arthritis & Rheumatology
- Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis
- (2018) Amanda Ricciuto et al. Journal of Crohns & Colitis
- Nobel work that galvanized an industry
- (2018) NATURE BIOTECHNOLOGY
- Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
- (2018) Jocelyn Quistrebert et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Recapture and improved outcome of pegloticase response with methotrexate–A report of two cases and review of the literature
- (2018) Sarah Y. Bessen et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials
- (2018) Soumi Gupta et al. EBioMedicine
- Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment
- (2017) Joachim R. Kalden et al. Nature Reviews Rheumatology
- Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories
- (2017) L. I. Bader et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Immunogenicity of Therapeutic Antibodies
- (2017) Karien Bloem et al. THERAPEUTIC DRUG MONITORING
- Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn’s disease: a systematic review and meta-analysis
- (2017) Karoline Freeman et al. BMJ Open
- Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors
- (2017) Moustafa Hamze et al. Frontiers in Immunology
- The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study
- (2017) Robert J. Moots et al. PLoS One
- High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
- (2016) Meghna Jani et al. ANNALS OF THE RHEUMATIC DISEASES
- The changing landscape of biosimilars in rheumatology
- (2016) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
- (2016) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals
- (2016) G. R. Gunn et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics
- (2016) Katherine L. Gill et al. CLINICAL PHARMACOKINETICS
- A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution
- (2016) Talia M. Muram et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors
- (2016) Carl I. Webster et al. mAbs
- Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
- (2016) Anette Karle et al. mAbs
- A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice
- (2016) Meghna Jani et al. RHEUMATOLOGY
- Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
- (2016) Murli Krishna et al. Frontiers in Immunology
- Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange
- (2016) Karin A. van Schie et al. Scientific Reports
- Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment
- (2015) Der-Yuan Chen et al. ANNALS OF THE RHEUMATIC DISEASES
- Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium
- (2015) B. Rup et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis
- (2015) David Ternant et al. CLINICAL PHARMACOKINETICS
- Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL
- (2015) Bárbara P. Fafá et al. CLINICAL RHEUMATOLOGY
- Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients
- (2015) Karien Bloem et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure
- (2015) Bella Ungar et al. MEDICINE
- Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice
- (2015) Thierry Schaeverbeke et al. RHEUMATOLOGY
- Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study
- (2015) Ariana Montes et al. ARTHRITIS RESEARCH & THERAPY
- Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis
- (2015) Meghna Jani et al. Arthritis & Rheumatology
- Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy
- (2015) Herbert S. B. Baraf et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
- (2015) Hsien-Yi Chiu et al. PLoS One
- Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial
- (2014) Casper Steenholdt et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up
- (2014) Erik H Vogelzang et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
- (2014) Gerd-Rűdiger Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study
- (2014) Roy Fleischmann et al. CURRENT MEDICAL RESEARCH AND OPINION
- Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis
- (2014) Diana Hernández-Flórez et al. RHEUMATOLOGY INTERNATIONAL
- Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients
- (2014) Michael S Hershfield et al. ARTHRITIS RESEARCH & THERAPY
- Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
- (2014) Peter E Lipsky et al. ARTHRITIS RESEARCH & THERAPY
- A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies
- (2013) Sandra Garcês et al. ANNALS OF THE RHEUMATIC DISEASES
- Key findings towards optimising adalimumab treatment: the concentration–effect curve
- (2013) Mieke F Pouw et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up
- (2013) Eva L Kneepkens et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
- (2013) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity of therapeutic proteins: Influence of aggregation
- (2013) Kirsty D. Ratanji et al. Journal of Immunotoxicology
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
- (2013) Pauline A. van Schouwenburg et al. Nature Reviews Rheumatology
- Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
- (2013) Herbert SB Baraf et al. ARTHRITIS RESEARCH & THERAPY
- Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experience
- (2012) Deeksha S. Bali et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS
- Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
- (2012) Fabien B Vincent et al. ANNALS OF THE RHEUMATIC DISEASES
- Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
- (2012) Charlotte L Krieckaert et al. ANNALS OF THE RHEUMATIC DISEASES
- The role of biosimilars in the treatment of rheumatic diseases
- (2012) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
- (2012) Pauline A van Schouwenburg et al. ANNALS OF THE RHEUMATIC DISEASES
- Transient Low-Dose Methotrexate Induces Tolerance to Murine Anti-Thymocyte Globulin and Together They Promote Long-Term Allograft Survival
- (2012) A. Joseph et al. JOURNAL OF IMMUNOLOGY
- When is switching warranted among biologic therapies in rheumatoid arthritis?
- (2012) Alan Reynolds et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients
- (2011) A Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: A case series and cohort study
- (2011) L. A. Korswagen et al. ARTHRITIS AND RHEUMATISM
- Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
- (2011) Klaus Bendtzen ARTHRITIS AND RHEUMATISM
- Pegloticase and Chronic Gout--Reply
- (2011) J. S. Sundy et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
- (2010) A. Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model
- (2010) A. Joseph et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Nathanael L. Dirks et al. CLINICAL PHARMACOKINETICS
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- Dealing with immunogenicity of biologicals: assessment and clinical relevance
- (2010) Gerrit J Wolbink et al. CURRENT OPINION IN RHEUMATOLOGY
- Human immunoglobulin allotypes
- (2010) Roy Jefferis et al. mAbs
- The immunogenicity of humanized and fully human antibodies
- (2010) Fiona A. Harding et al. mAbs
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
- (2009) G. M. Bartelds et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
- (2008) Shumpei Yokota et al. LANCET
- Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment
- (2008) Jinhai Wang et al. NATURE BIOTECHNOLOGY
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started